Skip to main content

Advertisement

Table 2 Summary of findings table: 21 excluded from meta-analysis shown by italics at first author's name

From: Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

# First author Year Pilot Power calc. ITT sample PP sample PP sample > median (62.5) Attrition rate % Original ITT analysis ‘Main’ outcome identified Nature of ‘main’ outcome End-point
A42 Aabel 2001 N N 51 51 N 0.0 N Daily symptom score (VAS) Continuous 10 days
A43 Aabel 2000 N Y 70 66 Y 5.7 N Daily symptom score Continuous 32 days
A44 Aabel 2000 N Y 80 73 Y 8.8 N Daily symptom score (VAS) Continuous 10 days
A47 Baker 2003 N Y ? 44 N ? N Revised Test Anxiety (RTA) scale Continuous 4 days
A48 bBalzarini 2000 N N 66 61 N 7.6 N Index of Total Severity during Recovery (re: skin colour, temp, oedema, pigmentation) Continuous 7–8 weeks
A49 bBeer 1999 N N 40 40 N 0.0 Y Time between to regular uterine contractions Continuous 7 h or induction of labour
A50 Belon 2006 N N 43 43 N 0.0 N Reversal in expression of antinuclear antibody titre Dichotomous 1 month
A51 Belon 2007 Y N 39 25 N 35.9 N Blood arsenic concentration Continuous 2 months
A52 bBergmann (a) 2000 N Y ? 37 N ? N Cycle normalisation Dichotomous 3 months or 3 cycles
A52 bBergmann (b) 2000 N Y ? 30 N ? Y Cycle normalisation Dichotomous 3 months or 3 cycles
A53 Bernstein 2006 N N 200 171 Y 14.5 N Psoriasis Area Severity Index Continuous 12 weeks
A55 Berrebi 2001 N N 71 71 Y 0.0 N Mammary pain (VAS) Continuous 4 days
A56 Bignamini 1987 N N 34 32 N 5.9 N (Systolic) Blood pressure Continuous 4 weeks
A59 bCialdella 2001 N Y 96 61 N 36.5 Y “Success rate” for clinical global impression Dichotomous 30 days
A60 Clark 2000 Y N 18 14 N 22.2 N Daily pain (100 mm VAS) Continuous 14 days
A272 Colau 2012 N Y 108 101 Y 6.5 Y Hot flash score Continuous 12 weeks
A61 Cornu 2010 Y Y 92 92 Y 0.0 Y Cumulated blood loss at drain removal Continuous Up to 7 d
A62 bDiefenbach 1997 N N 258 209 Y 19.0 Y Treatment success (‘very good’ + ‘good’ results) – physician-assessed Dichotomous Up to 3 weeks
A63 bErnst 1990 N N 122 a 122 a N 0.0 N Venous filling time Continuous 24 days
A64 bFerley 1989 N N 478 462 Y 3.3 N Proportion of patients recovered (from 5 cardinal symptoms and from temp > 37.5) Dichotomous By 48 h
A67 Frass 2005 N N 55 50 N 9.1 N Total volume of tracheal secretions per day Continuous 2 days
A68 bFreitas 1995 N N 86 69 Y 19.8 N Score of intensity, frequency and duration of symptoms Continuous 6 months
A69 Friese 2007 N N 144 68 Y 52.8 Y Sinusitis symptoms score Continuous 21 days
A70 bFriese 1997 N Y 97 82 Y 15.5 N Frequency of non-adenoidectomy (imputed) Dichotomous 3 months
A74 Gerhard (a) 1998 N Y 38 28 N 26.3 N Frequency of pregnancy Dichotomous 3 months
A74 Gerhard (b) 1998 N Y 27 21 N 22.2 N Frequency of pregnancy Dichotomous 3 months
A74 Gerhard (c) 1998 N Y 31 17 N 45.2 N Frequency of pregnancy Dichotomous 3 months
A75 GRECHO 1989 N Y 300 300 Y 0.0 N Number of hours from operation until first stool Continuous Up to c.100 h
A274 Harrison 2013 Y N 34 28 N 17.6 N Sleep onset latency Continuous 28 days
A76 Hart 1997 N N 93 73 Y 21.5 N Frequency of improved pain score (VAS) Dichotomous Duration of 5 days
A78 Hitzenberger 2005 N Y ? ? - ? N Blood pressure Continuous 6 weeks
A79 bHofmeyr 1990 Y N 162 161 Y 0.6 N Daily questionnaire responses: those without moderate/severe perineal pain Dichotomous 4 days
A80 Jacobs 2006 N N 292 265 Y 9.2 Y Duration of diarrhoea Continuous Up to 7 days
A81 Jacobs 2007 Y N 60 58 N 1.7 N No. of days until no pain or fever for at least two consecutive days Continuous Up to 1 weeks
A83 bKaziro 1984 N N 77 77 Y 0.0 N Pain score (VAS): Numbers without moderate/severe pain (imputed) Dichotomous 8 days
A84 Khuda-Bukhsh 2005 Y N 55 55 N 0.0 N Urine arsenic concentration (imputed) Continuous 11 days
A85 Khuda-Bukhsh 2011 Y N 28 14 N 50.0 N Urine arsenic concentration Continuous 2 months
A86 Kim 2005 Y Y 40 34 N 15.0 Y Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ total symptoms) Continuous 4 weeks
A88 Kolia-Adam 2008 N N 30 30 N 0.0 N Hours of sleep per night Continuous 8 weeks
A89 Kotlus 2010 N N 60 57 N 5.0 N Area of ecchymosis Continuous 7 days
A91 Labrecque 1992 N Y 174 162 Y 6.9 N Proportion of pts with healed warts (physician assessment) Dichotomous 18 weeks
A92 bLeaman 1989 N N 34 34 N 0.0 N Pain (0-10 VAS) - area-under-the-curve Continuous 6 h
A93 Lewith 2002 N N 242 202 Y 16.5 Y Asthma VAS (imputed) Continuous 16 weeks
A94 Lipman 1999 N N 101 90 Y 10.9 N Average snoring score computed from responses to Snore Diary over last 5 nights of 10 Continuous Duration of 10 days
A293 Malapane 2014 Y N 30 30 N 0.0 N Tonsillitis pain score (Wong-Baker FACES) Continuous 6 days
A95 McCutcheon 1996 N N 77 58 N 24.7 N State Anxiety score Continuous Duration of 15 days
A275 Naidoo 2013 Y N 30 30 N 0.0 N Wheal diameter Continuous 4 weeks
A100 Oberbaum 2001 N N 32 30 N 6.3 Y Area-under-the-curve score for stomatitis symptoms (severity and duration) (imputed) Continuous 14 days minimum
A101 bOberbaum 2005 Y N 45 40 N 11.1 Y Venous haemoglobin Continuous 72 h postpartum
A103 Padilha 2011 N N 131 120 Y 8.4 Y Proportion of workers with Pb decrease of at least 25% (imputed) Dichotomous 30 days
A104 bPapp 1998 N N 372 334 Y 10.2 N Proportion of patients with physician-assessed recovery in health (i.e. ‘no symptoms’) Dichotomous By 48 h
A105 Paris 2008 N Y 131 105 Y 19.8 Y Proportion patients with cumulated consumption of morphine < 10 mg/day (imputed) Dichotomous 24 h post-op
A108 bRahlfs 1976 Y Y ? 63 Y ? N Improvement of irritable bowel syndrome (scale 1 + 2) Dichotomous 14 days
A109 bRahlfs 1978 Y N 119 85 Y 28.6 N Improvement of irritable bowel syndrome (scale 3 + 4) Dichotomous 15 days
A277 Razlog 2012 Y N 20 18 N 10.0 N Conner’s PSQ (‘Impulsivity and/or hyperactivity’ category) Continuous 3 weeks
A111 bReilly 1986 N Y 158 109 Y 31.6 N Propn. with improvement in daily overall VAS score (imputed) Dichotomous 5 weeks
A112 bReilly 1994 N Y 28 24 N 14.3 Y Propn. with improvement in daily overall VAS score Dichotomous 4 weeks
A113 Robertson 2007 N Y 190 111 Y 41.6 N Tonsillectomy pain (VAS) score Continuous 14 days
A116 Schmidt 2002 N Y 208 194 Y 6.7 Y Reduction of body weight Continuous 3 days
A117 Seeley 2006 N N 29 26 N 10.3 N Area of ecchymosis Continuous 10 days
A278 Sencer 2012 N Y 195 106 Y 45.6 N Sum of Walsh scores for mucositis Continuous Up to 20 days post-transplant
A120 Singer 2010 N Y 80 79 Y 1.3 Y Area-under-the-curve pain score Continuous 14 days
A122 Stevinson 2003 Y N 64 62 N 3.1 Y Pain (Short Form McGill Pain Questionnaire Continuous 14 days
A123 bTaylor 2000 N Y 51 50 N 2.0 Y Daily overall VAS score (imputed) Continuous 3–4 weeks
A125 Tveiten 1991 N N 44 36 N 18.2 N Muscle soreness (VAS) (imputed) Continuous 3 days
A126 bTveiten 1998 N N ? 46 N ? N Muscle soreness (VAS) Continuous 3 days
A128 bVickers 1998 N Y ? 400 Y ? Y Muscle soreness (VAS) Continuous 2 days
A130 Weiser 1994 N Y 173 155 Y 10.4 N Sinusitis score Continuous 5 months or on relapse
A131 bWiesenauer 1985 N N 106 74 Y 30.2 N Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’ Dichotomous 4 weeks
A132 Wiesenauer 1989 N N 221 152 Y 31.2 N Sinusitis score Continuous 3–4 weeks
A133 bWiesenauer 1990 N N 243 171 Y 29.6 N Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’ Dichotomous Approx 5 weeks
A134 Wiesenauer 1991 N N 176 106 Y 39.8 N Treatment success Dichotomous 12 weeks
A135 bWiesenauer 1995 N N 132 120 Y 9.1 N Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’ Dichotomous 4 weeks
A136 Wolf 2003 Y N 60 59 N 1.7 N Haematoma area Continuous 2 weeks
A137 Zabolotnyi 2007 N Y 113 113 Y 5.3 Y Sinusitis severity score cf. Day 0 (imputed) Continuous 7 days
  1. ITT intention to treat, PP per protocol, Y yes, N no
  2. aSample size refers to number of legs, not the number of subjects, in the trial
  3. bIncluded in meta-analysis by Shang et al. [http://www.ispm.unibe.ch/unibe/portal/fak_medizin/ber_vkhum/inst_smp/content/e93945/e93964/e180045/e180897/1433.Study_characteristics_of_homoeopathy_studies_corrected_eng.pdf (accessed 1 July 2016)]
Back to article page